HCID 69087699, 화합물 → HCID 69087702, 화합물
반응식
[CH3:1][C:2]1[CH:7]=[CH:6][C:5]([C:8]2[N:9]=[C:10]3[C:16]4[CH:17]=[CH:18][CH:19]=[CH:20][C:15]=4[NH:14][C:13]4[N:21]=[CH:22][CH:23]=[CH:24][C:12]=4[N:11]3[C:25]=2[C:26]2[CH:31]=[CH:30][C:29]([C:32]3([NH:36][C:37](=[O:43])[O:38][C:39]([CH3:42])([CH3:41])[CH3:40])[CH2:35][CH2:34][CH2:33]3)=[CH:28][CH:27]=2)=[CH:4][C:3]=1[N+:44]([O-])=O>CO.[Pd]>[NH2:44][C:3]1[CH:4]=[C:5]([C:8]2[N:9]=[C:10]3[C:16]4[CH:17]=[CH:18][CH:19]=[CH:20][C:15]=4[NH:14][C:13]4[N:21]=[CH:22][CH:23]=[CH:24][C:12]=4[N:11]3[C:25]=2[C:26]2[CH:31]=[CH:30][C:29]([C:32]3([NH:36][C:37](=[O:43])[O:38][C:39]([CH3:41])([CH3:40])[CH3:42])[CH2:33][CH2:34][CH2:35]3)=[CH:28][CH:27]=2)[CH:6]=[CH:7][C:2]=1[CH3:1]참가 물질
실험 절차
10% Pd/C (50.0 mg) was added to a solution of tert-butyl (1-{4-[2-(4-methyl-3-nitrophenyl)-9H-imidazo[1,2-d]pyrido[2,3-b][1,4]benzodiazepin-3-yl]phenyl}cyclobutyl)carbamate (49.1 mg, 0.0799 mmol) in MeOH (5 mL), and the mixture was stirred for 6.5 hours under hydrogen atmosphere. The catalyst was filtered off and washed with MeOH. The combined filtrate and washings were concentrated, and the residue was purified by silica gel column chromatography (EtOAc/hexane=1:2→1:1→2:1→EtOAc) to afford desired product (28.2 mg, 60.4%) as pale yellow solid. 1HNMR (CDCl3) 400 MHz δ: 8.17 (dd, J=7.8, 1.4 Hz, 1H), 8.00 (dd, J=5.0, 1.4 Hz, 1H), 7.39-7.31 (m, 2H), 7.27 (td, J=7.7, 1.5 Hz, 1H), 7.21-6.69 (m, 8H), 6.58 (dd, J=7.8, 4.6 Hz, 1H), 6.52-6.46 (m, 1H), 5.24 (br s, 1H), 3.56 (br s, 2H), 2.63-2.27 (m, 4H), 2.19-2.06 (m, 1H), 2.14 (s, 3H), 1.95-1.74 (m, 1H), 1.38 (br s, 9H).
후처리
- filtrationThe catalyst was filtered off
- washwashed with MeOH
- concentrationThe combined filtrate and washings were concentrated
- customthe residue was purified by silica gel column chromatography (EtOAc/hexane=1:2→1:1→2:1→EtOAc)
출처 및 근거
- ORD 기록
- ord-b4053ba6275e46d1ad06d5c1b69f1e85
- 출처 데이터셋
- uspto-grants-2013_10
- 특허 번호
- US08569331B2
반응 노트
불러오는 중…